Skip to main content

Table 2 Summary of metabolic markers at baseline and on the last day of combination therapy.

From: Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study

  T/HCTZ V/HCTZ Difference* (T/HCTZ – V/HCTZ)
Endpoint, mean ± SD Baseline Last day Baseline Last day p value
Serum triglyceride (mg/dL) 201.7 ± 247 211.8 ± 172 196.3 ± 151 210.5 ± 177 0.91
LDL-C (mg/dL) 165.6 ± 35.4 169.8 ± 38.1 162.8 ± 33.9 165.3 ± 36.0 0.17
HDL-C (mg/dL) 37.1 ± 6.5 36.6 ± 6.3 37.6 ± 7.2 37.1 ± 7.0 0.64
Total cholesterol (mg/dL) 195.7 ± 23.3 198.5 ± 21.7 194.5 ± 19.8 196.3 ± 20.9 0.20
Potassium (mEq/L) 4.4 ± 0.4 4.5 ± 0.4 4.4 ± 0.4 4.4 ± 0.4 0.03
Glucose (mg/dL) 128.8 ± 44.1 138.8 ± 53.1 134.1 ± 49.2 140.4 ± 55.2 0.58
HbA1c (%) 6.5 ± 0.3 6.6 ± 0.3 6.6 ± 0.3 6.7 ± 0.4 0.93
Albumin:creatinine ratio 97.6 ± 330 65.1 ± 266 66.7 ± 239 45.1 ± 177 0.97
  1. T/HCTZ: telmisartan 80 mg plus HCTZ 12.5 mg; V/HCTZ: valsartan 160 mg plus HCTZ 12.5 mg; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; HbA1c: glycolated haemoglobin.
  2. *Analysis of change from baseline